Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-03-11 00:00:00 ET · period of report 2022-03-09 · accession 0000899243-22-010801 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-11 | 2022-03-09 | ARQT | Watanabe Todd Franklin | Pres, CEO, Dir | S - Sale | $17.00 | -300 | 660.7K | -0.0% | -$5,100 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-09 | S | D | 300 | $17.00 | 660,667 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. (F2) Includes 109,925 restricted stock units "RSUs". The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. |